Claims
- 1. A method for diagnosing a vascular condition in an individual, comprising the steps of:
iii) measuring the quantity of a RTP/Drg1 gene product in at least one biological sample obtained from said individual; and iv) comparing the measured quantity of said RTP/Drg1 gene product to a standard value for the quantity of RTP/Drg1 gene product in a normal biological sample; wherein an increase in the measured quantity of said RTP/Drg1 gene product relative to the standard value is indicative of said vascular condition.
- 2. The method of claim 1 wherein said standard value is a measured quantity of said RTP/Drg1 gene product in a different biological sample, said different biological sample being substantially unaffected by a vascular condition associated with a reduction in blood flow.
- 3. The method of claim 2 wherein said the biological sample and said different biological sample are obtained from the same individual.
- 4. The method of claim 3 wherein said different biological sample is obtained prior to the onset of said vascular condition.
- 5. The method of claim 1 wherein said standard value is obtained from a data bank.
- 6. The method of claim 1 wherein said vascular condition is selected from the group consisting of peripheral vascular disease, cancer, preeclampsia, renal failure, erectile dysfunction, abnormal pregnancy, heart disease and stroke.
- 7. The method of claim 1 wherein said gene product is RNA.
- 8. The method of claim 1 wherein said gene product is a polypeptide or an antibody binding fragment thereof.
- 9. The method of claim 1 wherein said biological sample is selected from the group consisting of leukocytes, blood, serum, plasma, saliva, urine and tissue.
- 10. A method for detecting hypoxia of endothelial dysfunction in an individual, comprising the steps of:
i) measuring the quantity of a RTP/Drg1 gene product in at least one biological sample obtained from said individual; and ii) comparing the measured quantity of said RTP/Drg1 gene product to a standard value for the quantity of RTP/Drg1 gene product in a normal biological sample; wherein an increase in the measured quantity of said RTP/Drg1 gene product relative to the standard value is indicative of hypoxia or endothelial dysfunction.
- 11. The method of claim 10 wherein said standard value is a measured quantity of said RTP/Drg1 gene product in a different biological sample, said different biological sample being substantially unaffected by hypoxia or endothelial dysfunction.
- 12. The method of claim 11 wherein said the biological sample and said different biological sample are obtained from the same individual.
- 13. The method of claim 12 wherein said different biological sample is obtained prior to the onset of hypoxia or endothelial dysfunction.
- 14. The method of claim 10 wherein said standard value is obtained from a data bank.
- 15. The method of claim 10 wherein said gene product is RNA.
- 16. The method of claim 10 wherein said gene product is a polypeptide or an antibody binding fragment thereof.
- 17. The method of claim 10 wherein said biological sample is selected from the group consisting of leukocytes, blood, serum, plasma, saliva, urine and tissue.
- 18. A method for detecting hypoxia or endothelial dysfunction in an individual, comprising the steps of:
i) measuring the quantity of a PAI-1 gene product in at least one biological sample obtained from said individual; and ii) comparing the measured quantity of said PAI-1 gene product to a standard value for the quantity of PAI-1 gene product in a normal biological sample; wherein an increase in the measured quantity of said PAI-1 gene product relative to the standard value is indicative of hypoxia or endothelial dysfunction.
- 19. The method of claim 18 wherein said standard value is a measured quantity of said PAI-1 gene product in a different biological sample, said different biological sample being substantially unaffected by hypoxia or endothelial dysfunction.
- 20. The method of claim 19 wherein said the biological sample and said different biological sample are obtained from the same individual.
- 21. The method of claim 20 wherein said different biological sample is obtained prior to the onset of said hypoxia or endothelial dysfunction.
- 22. The method of claim 18 wherein said standard value is obtained from a data bank.
- 23. The method of claim 18 wherein said gene product is RNA.
- 24. The method of claim 18 wherein said gene product is a polypeptide or an antibody binding fragment thereof.
- 25. The method of claim 18 wherein said biological sample is selected from the group consisting of leukocytes, blood, serum, plasma, saliva, urine and tissue.
- 26. A method for detecting hypoxia or endothelial dysfunction in an individual, comprising the steps of:
i) measuring the quantity of a uPAR gene product in at least one biological sample obtained from said individual; and ii) comparing the measured quantity of said uPAR gene product to a standard value for the quantity of uPAR gene product in a normal biological sample; wherein an increase in the measured quantity of said uPAR gene product relative to the standard value is indicative of hypoxia or endothelial dysfunction.
- 27. The method of claim 26 wherein said standard value is a measured quantity of said uPAR gene product in a different biological sample, said different biological sample being substantially unaffected by hypoxia or endothelial dysfunction.
- 28. The method of claim 17 wherein said the biological sample and said different biological sample are obtained from the same individual.
- 29. The method of claim 28 wherein said different biological sample is obtained prior to the onset of hypoxia or endothelial dysfunction.
- 30. The method of claim 26 wherein said standard value is obtained from a data bank.
- 31. The method of claim 26 wherein said gene product is RNA.
- 32. The method of claim 26 wherein said gene product is a polypeptide or an antibody binding fragment thereof.
- 33. The method of claim 26 wherein said biological sample is selected from the group consisting of leukocytes, blood, serum, plasma, saliva, urine and tissue.
- 34. A method for detecting hypoxia or endothelial dysfunction in an individual, comprising the steps of:
i) measuring the quantity of an arginine metabolite in at least one biological sample obtained from said individual; and ii) comparing the measured quantity of said arginine metabolite to a standard value for the quantity of said arginine metabolite in a normal biological sample; wherein an increase in the measured quantity of said arginine metabolite relative to the standard value is indicative of hypoxia or endothelial dysfunction.
- 35. The method of claim 28 wherein said arginine metabolite is ADMA or L-NMMA.
- 36. A method of assessing an individual's risk for a vascular condition comprising the steps of:
i) measuring the quantity of a RTP/Drg1 gene product in at least one biological sample obtained from said individual; and ii) comparing the measured quantity of said RTP/Drg1 gene product to a standard value for the quantity of RTP/Drg1 gene product in a normal biological sample; wherein an increase in the measured quantity of said RTP/Drg1 gene product relative to the standard value is indicative of risk for said vascular condition, and said risk correlates with the degree to which said RTP/Drg1 gene product is elevated.
- 37. A method for detecting hypoxia or endothelial dysfunction in an individual, comprising the steps of:
i) isolating cells from said individual; ii) measuring the invasiveness or of said cells in an in vitro cellular invasion assay; and iii) comparing the measured value to a standard value for said cells; wherein an increase in invasiveness relative to said standard is indicative of hypoxia or endothelial dysfunction.
- 38. A method for assessing an individual's risk for metastasis, comprising the steps of:
i) isolating cells from said individual; ii) measuring the invasiveness of said cells in an in vitro cellular invasion assay; and iii) comparing the measured value to a standard value for said cells; wherein an increase in invasiveness relative to said standard is indicative of an increased risk for metastasis.
- 39. A method for assessing an individual's risk for metastasis, comprising the steps of:
i) measuring the quantity of at least one substance in at least one biological sample obtained from said individual; and ii) comparing the measured quantity of said substance to a standard value for the quantity of said substance in a normal biological sample; wherein an increase in the measured quantity of said substance relative to the standard value is indicative of an increased risk for metastasis.
- 40. The method of claim 39 wherein said substance is selected from the group consisting of a RTP/Drg1 gene product, a uPAR gene product, a PAI-1 gene product and an arginine metabolite.
- 41. The method of claim 40 wherein said biological sample consists of non-cancerous cells.
- 42. A method for diagnosing a vascular condition in an individual, comprising the step of:
i) detecting at least one endocrine disrupter in at least one biological sample obtained from said individual; wherein the presence of said endocrine disrupter is indicative of said vascular condition.
- 43. The method of claim 42 wherein said endocrine disrupter is p,p-DDE.
- 44. The method of claim 43 wherein said vascular condition is erectile dysfunction.
- 45. A method for assessing an individual's risk for contracting a vascular condition, comprising the steps of:
i) measuring the quantity of at least one endocrine disrupter in at least one biological sample obtained from said individual; ii) measuring the quantity of an endogenous hormone in said biological sample; and iii) determining the ratio of said disrupter to said endogenous hormone in said biological sample; wherein the risk is proportional to said ratio.
- 46. The method of claim 45 wherein said endocrine disrupter is p,p-DDE and said endogenous hormone is testosterone.
- 47. The method of claim 46 wherein said vascular disorder is erectile dysfunction.
- 48. A method of diagnosing a vascular condition in an individual, comprising the steps of:
i) measuring the quantity of at least two substances chosen from the group consisting of a product of the RTP/Drg1 gene, a product of the uPAR gene, a product of the PAI-1 gene and a product of abnormal arginine metabolism, in at least one biological sample obtained from said individual; and ii) comparing the measured quantity of said substances to a standard value for the quantity of said substances in a normal biological sample; wherein an increase in the measured quantity of at least one of said substances relative to the standard value is indicative of said vascular condition.
- 49. The method of claim 48 further comprising
i) isolating cells from said individual; ii) measuring the invasiveness of said cells in an in vitro cellular invasion assay; and iii) comparing the measured value to a standard value for said cells; wherein an increase in invasiveness or an increase in the measured quantity of at least one of said substances relative to the standard value is indicative of said vascular condition.
- 50. A method of diagnosing hypoxia or endothelial dysfunction in an individual, comprising the steps of:
i) measuring the quantity of at least two substances chosen from the group consisting of a product of the RTP/Drg1 gene, a product of the uPAR gene, a product of the PAI-1 gene and a product of abnormal arginine metabolism, in at least one biological sample obtained from said individual; and ii) comparing the measured quantity of said substances to a standard value for the quantity of said substances in a normal biological sample; wherein an increase in the measured quantity of at least one of said substances relative to the standard value is indicative of said hypoxia or endothelial dysfunction.
RELATED APPLICATION
[0001] This application claims the benefit of Provisional Application No. 60/083,763, filed May 1, 1998, the entire teachings of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60083763 |
May 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09302554 |
Apr 1999 |
US |
Child |
10059920 |
Jan 2002 |
US |